Genmab ASMEX:GMABN 92 Market Cap is MXN282,889 Mil as of Jun. 26, 2026. GuruFocus rates MEX:GMABN with a GF Score™ of 92/100 and a GF Value™ of MXN5,328.99 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,431 Biotechnology companies, Genmab AS ranks better than 98.6% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Genmab AS's share price for the quarter that ended in Mar. 2026 was MXN4572.94. Genmab AS's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 61 Mil. Therefore, Genmab AS's market cap for the quarter that ended in Mar. 2026 was MXN280,737 Mil.
Genmab AS's quarterly market cap
increased
from Sep. 2025 (MXN319,105 Mil) to Dec. 2025 (MXN347,104 Mil) but then
declined
from Dec. 2025 (MXN347,104 Mil) to Mar. 2026 (MXN280,737 Mil).
Genmab AS's annual market cap
declined
from Dec. 2023 (MXN348,950 Mil) to Dec. 2024 (MXN324,054 Mil) but then
increased
from Dec. 2024 (MXN324,054 Mil) to Dec. 2025 (MXN347,104 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Genmab AS's Enterprise Value for Today is MXN350,409 Mil.
Genmab AS (MEX:GMABN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Genmab AS Market Cap Related Terms
Genmab AS Market Cap Historical Data
* Premium members only.
The historical data trend for Genmab AS's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GMABN vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Genmab AS's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Market Cap distribution charts can be found below:
* The bar in red indicates where Genmab AS's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Genmab AS's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (MEX:GMABN) has a Market Cap of MXN282,889 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Genmab AS and its competitors. According to the industry distribution chart, Genmab AS ranks #20 out of 1431 companies in the Biotechnology industry, placing it in the top 1.4%.
Is Genmab AS's Market Cap too high?
Genmab AS's current Market Cap is MXN282,889 Mil. Based on the distribution chart, Genmab AS ranks #20 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #20 out of 1431 companies for Market Cap. This places Genmab AS in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Genmab AS and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current Market Cap is MXN282,889 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,328.99, compared to a current price of MXN4,027.79 — trading 24.4% below its estimated fair value. The current Market Cap is MXN282,889 Mil. Genmab AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current Market Cap is MXN282,889 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (MEX:GMABN) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of MXN4,027.79 is trading 24.4% below its estimated GF Value™ of MXN5,328.99.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for MEX:GMABN:
Market Cap: MXN282,889 Mil
GF Value™: MXN5,328.99 vs. price of MXN4,027.79 (24.4% below fair value)
No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
92GF Score
Get the complete analysis for MEX:GMABN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GMABN has been successfully added to your 
